SLC17A9 and breast carcinoma: Solute carrier family 17 member 9 (SLC17A9) was involved in the progression of colorectal cancer (CRC) and breast cancer and was recognized as a potential biomarker for outcome prediction of CRC and BC patients [46, 47].